{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:43Z","timestamp":1786985443928,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bone.2026.117874","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:59:48Z","timestamp":1774940388000},"page":"117874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Denosumab-induced hypocalcemia: detection of drug-drug interactions using disproportionality analysis in VigiBase\u00ae"],"prefix":"10.1016","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9466-7110","authenticated-orcid":false,"given":"Benjamin","family":"Batteux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gras-Champel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-8258","authenticated-orcid":false,"given":"Martine","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8693-4212","authenticated-orcid":false,"given":"Mohamad Houssam","family":"Al Balkhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0186-4797","authenticated-orcid":false,"given":"Youssef","family":"Bennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2026.117874_bb0005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12020-020-02324-2","article-title":"Diagnosis and management of hypocalcemia","volume":"69","author":"Pepe","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.bone.2026.117874_bb0010","unstructured":"Prolia - Summary of Product Characteristics (SmPC) - (emc), (n.d.). https:\/\/www.medicines.org.uk\/emc\/product\/568\/smpc (accessed May 10, 2022)."},{"key":"10.1016\/j.bone.2026.117874_bb0015","unstructured":"Xgeva - Summary of product characteristics, (n.d.). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xgeva-epar-product-information_en.pdf (accessed August 6, 2025)."},{"key":"10.1016\/j.bone.2026.117874_bb0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/clinem\/dgac621","article-title":"Treatment of hypercalcemia of malignancy in adults: an endocrine society clinical practice guideline","volume":"108","author":"El-Hajj Fuleihan","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2026.117874_bb0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bone.2026.117874_bb0030","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"FREEDOM Trial, Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2026.117874_bb0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00774-020-01180-4","article-title":"Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study","volume":"39","author":"Tanaka","year":"2021","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2026.117874_bb0040","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00198-019-05261-7","article-title":"Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?","volume":"31","author":"Tsvetov","year":"2020","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.117874_bb0045","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2147\/TCRM.S123172","article-title":"High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis","volume":"12","author":"Ishikawa","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.bone.2026.117874_bb0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bone.2026.117874_bb0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1078155216628325","article-title":"Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis","volume":"23","author":"Yerram","year":"2017","journal-title":"J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract."},{"key":"10.1016\/j.bone.2026.117874_bb0060","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/pds.4045","article-title":"Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting","volume":"25","author":"Huynh","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bone.2026.117874_bb0065","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00198-023-06926-0","article-title":"Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection","volume":"35","author":"Sp\u00e5ngeus","year":"2024","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.117874_bb0070","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00774-009-0119-x","article-title":"A review of drug-induced hypocalcemia","volume":"27","author":"Liamis","year":"2009","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2026.117874_bb0075","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40780-024-00380-8","article-title":"Influence of loop diuretics on denosumab-induced hypocalcaemia in osteoporosis: a retrospective observational analysis","volume":"10","author":"Hirai","year":"2024","journal-title":"J. Pharm. Health Care Sci."},{"key":"10.1016\/j.bone.2026.117874_bb0080","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00223-020-00754-8","article-title":"A simple-to-use score for identifying individuals at high risk of denosumab-associated hypocalcemia in postmenopausal osteoporosis: a real-world cohort study","volume":"107","author":"Kim","year":"2020","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2026.117874_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2024.108190","article-title":"Exploration of factors affecting denosumab-induced hypocalcemia in male patients with osteoporosis using a hospital-based administrative claims database","volume":"193","author":"Kamimura","year":"2025","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2026.117874_bb0090","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/jcph.2057","article-title":"Development of risk prediction model for grade 2 or higher hypocalcemia in patients with bone metastasis treated with denosumab plus cholecalciferol (vitamin D3 )\/calcium supplement","volume":"62","author":"Ikegami","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2026.117874_bb0095","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41598-020-80243-y","article-title":"Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis","volume":"11","author":"Kanbayashi","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2026.117874_bb0100","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2026.117874_bb0105","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2125.2007.02900.x","article-title":"Detecting signals of drug\u2013drug interactions in a spontaneous reports database","volume":"64","author":"Thakrar","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2026.117874_bb0110","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.bone.2026.117874_bb0115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The Medical Dictionary for Regulatory Activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"10.1016\/j.bone.2026.117874_bb0120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bone.2026.117874_bb0125","unstructured":"Uppsala Monitoring Center, vigiMethods, (n.d.). https:\/\/who-umc.org\/research\/vigimethods\/ (accessed July 10, 2025)."},{"key":"10.1016\/j.bone.2026.117874_bb0130","unstructured":"Vigibase, (n.d.). https:\/\/www.who-umc.org\/vigibase\/vigibase\/."},{"key":"10.1016\/j.bone.2026.117874_bb0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","article-title":"vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues","volume":"37","author":"Bergvall","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.bone.2026.117874_bb0140","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.therap.2024.03.002","article-title":"Impact of the vaccination against SARS-CoV-2 campaign on disproportionality indicator from the WHO pharmacovigilance database: a competition bias study from case\/non-case analysis","volume":"79","author":"Adja\u00ef","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.bone.2026.117874_bb0145","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/pds.4682","article-title":"Impact of the \u201cFrench Levothyrox crisis\u201d on signal detection in the World Health Organization pharmacovigilance database","volume":"27","author":"Khouri","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bone.2026.117874_bb0150","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bone.2026.117874_bb0155","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1109\/TITB.2005.855566A","article-title":"Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance","volume":"9","author":"Roux","year":"2005","journal-title":"IEEE Trans. Inf. Technol. Biomed."},{"key":"10.1016\/j.bone.2026.117874_bb0160","doi-asserted-by":"crossref","unstructured":"M. Fusaroli, F. Salvo, B. Begaud, T.M. AlShammari, A. Bate, V. Battini, A. Brueckner, G. Candore, C. Carnovale, S. Crisafulli, P.M. Cutroneo, C. Dolladille, M.-D. Drici, J.-L. Faillie, A. Goldman, M. Hauben, M.T. Herdeiro, O. Mahaux, K. Manlik, F. Montastruc, Y. Noguchi, G.N. Nor\u00e9n, R. Noseda, I.J. Onakpoya, A. Pariente, E. Poluzzi, M. Salem, D. Sartori, N.T.H. Trinh, M. Tuccori, F. van Hunsel, E. van Puijenbroek, E. Raschi, C. Khouri, The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement, Drug Saf. (n.d.). doi:https:\/\/doi.org\/10.1007\/s40264-024-01421-9.","DOI":"10.1007\/s40264-024-01421-9"},{"key":"10.1016\/j.bone.2026.117874_bb0165","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2013"},{"key":"10.1016\/j.bone.2026.117874_bb0170","series-title":"StatPearls","article-title":"Cinacalcet","author":"Junaid","year":"2025"},{"key":"10.1016\/j.bone.2026.117874_bb0175","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.117874_bb0180","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13181-016-0543-y","article-title":"A RANKL wrinkle: denosumab-induced hypocalcemia","volume":"12","author":"Laskowski","year":"2016","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.bone.2026.117874_bb0185","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.kint.2017.07.021","article-title":"Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation","volume":"92","author":"Pimentel","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2026.117874_bb0190","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00223-020-00779-z","article-title":"Bone fragility fractures in CKD patients","volume":"108","author":"Pimentel","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2026.117874_bb0195","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ckj\/sft014","article-title":"Prolonged hypocalcaemia following a single dose of 60 mg denosumab in two patients with CKD 4\/5 on cinacalcet treatment for tertiary hyperparathyroidism","volume":"6","author":"Ivanov","year":"2013","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.bone.2026.117874_bb0200","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"International workshop on primary hyperparathyroidism, evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.117874_bb0205","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bone.2026.117874_bb0210","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1365-2362.2003.01103.x","article-title":"Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in postmenopausal osteopenic women","volume":"33","author":"Rejnmark","year":"2003","journal-title":"Eur. J. Clin. Investig."},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2026.117874_bb0215","first-page":"S2","article-title":"The effect of proton pump-inhibiting drugs on mineral metabolism","volume":"104","author":"Insogna","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bone.2026.117874_bb0220","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF02556841","article-title":"Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro","volume":"38","author":"Tuukkanen","year":"1986","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2026.117874_bb0225","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s12325-024-03028-z","article-title":"Baseline characteristics of the DISCOVER CKD prospective cohort","volume":"42","author":"Pollock","year":"2025","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bone.2026.117874_bb0230","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2147\/CIA.S180614","article-title":"High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis","volume":"13","author":"Ishikawa","year":"2018","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.bone.2026.117874_bb0235","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/cpt.277","article-title":"Pharmacoepidemiologic methods for studying the health effects of Drug-Drug Interactions (DDIs)","volume":"99","author":"Hennessy","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bone.2026.117874_bb0240","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jclinepi.2021.01.015","article-title":"Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases","volume":"134","author":"Khouri","year":"2021","journal-title":"J. Clin. Epidemiol."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:29:22Z","timestamp":1784233762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328226001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"alternative-id":["S8756328226001006"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.117874","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denosumab-induced hypocalcemia: detection of drug-drug interactions using disproportionality analysis in VigiBase\u00ae","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.117874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117874"}}